pioglitazone has been researched along with Macular Edema in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Macular Edema: Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the early association between pioglitazone and diabetic macular edema (DME)." | 7.79 | [Association between pioglitazone and diabetic macular edema]. ( Hoshikawa, Y; Ohkoshi, K, 2013) |
| "We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy." | 7.74 | Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. ( Asaumi, N; Kumagai, K; Mitamura, Y; Oshitari, T; Watanabe, M, 2008) |
| "To assess the early association between pioglitazone and diabetic macular edema (DME)." | 3.79 | [Association between pioglitazone and diabetic macular edema]. ( Hoshikawa, Y; Ohkoshi, K, 2013) |
| "We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy." | 3.74 | Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. ( Asaumi, N; Kumagai, K; Mitamura, Y; Oshitari, T; Watanabe, M, 2008) |
| "Patients with type II diabetes mellitus were categorized into 2 groups depending on TZD intake." | 1.39 | Impact of thiazolidinediones on macular thickness and volume in diabetic eyes. ( Al Shaar, L; Azar, S; Bashshur, ZF; El-Mollayess, GM; Salti, HI, 2013) |
| ": The aim of the study was to verify if the analysis of a large spontaneous reporting database could generate early signals on these adverse drug reactions (ADRs) associated with TZDs." | 1.38 | Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. ( Biagi, C; Marchesini, G; Marra, A; Motola, D; Piccinni, C; Poluzzi, E; Raschi, E, 2012) |
| "We evaluated, in patients with type 2 diabetes (T2D), the short-term and long-term risks of developing DME among users vs nonusers of thiazolidinediones." | 1.38 | Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. ( Donnelly, R; Idris, I; Warren, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gokce, G | 1 |
| Durukan, AH | 1 |
| Erdurman, FC | 1 |
| Ceylan, OM | 1 |
| Sobaci, G | 1 |
| Hoshikawa, Y | 1 |
| Ohkoshi, K | 1 |
| Azar, S | 1 |
| El-Mollayess, GM | 1 |
| Al Shaar, L | 1 |
| Salti, HI | 1 |
| Bashshur, ZF | 1 |
| Fong, DS | 1 |
| Contreras, R | 1 |
| Oshitari, T | 1 |
| Asaumi, N | 1 |
| Watanabe, M | 1 |
| Kumagai, K | 1 |
| Mitamura, Y | 1 |
| Lambley, RG | 1 |
| Vahdani, K | 2 |
| Konstantinidis, A | 1 |
| Booth, A | 1 |
| Motola, D | 1 |
| Piccinni, C | 1 |
| Biagi, C | 1 |
| Raschi, E | 1 |
| Marra, A | 1 |
| Marchesini, G | 1 |
| Poluzzi, E | 1 |
| Idris, I | 1 |
| Warren, G | 1 |
| Donnelly, R | 1 |
8 other studies available for pioglitazone and Macular Edema
| Article | Year |
|---|---|
Pioglitazone associated diabetic macular oedema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetes Mellitus, Type 2; | 2012 |
[Association between pioglitazone and diabetic macular edema].
Topics: Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Female; Humans; Hypoglycemic Agents; Macular E | 2013 |
Impact of thiazolidinediones on macular thickness and volume in diabetic eyes.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Gly | 2013 |
Glitazone use associated with diabetic macular edema.
Topics: Adult; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Glycated Hemoglobin; Hum | 2009 |
Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diuretics; Female; Fluorescein Angiography; | 2008 |
Rosiglitazone and pioglitazone. Beware macular oedema.
Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular E | 2009 |
Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
Topics: Adverse Drug Reaction Reporting Systems; Bone and Bones; Cardiovascular System; Clinical Trials as T | 2012 |
Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies | 2012 |